Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Nkarta, Inc. (NKTX)

Nkarta reports initial NKX019 trial data in myositis and systemic sclerosis

Positive Impact 4 of 5 other

Nkarta reported initial clinical data for NKX019, its allogeneic CAR NK cell therapy candidate, in myositis and systemic sclerosis, based on small patient groups with limited follow-up. Among 40 patients treated across five indications, the company reported no deaths and no treatment discontinuations due to adverse events, and it has amended its dosing schedule and plans upcoming FDA discussions on registrational pathways.

Key points

  • Myositis: 5 of 6 patients (83%) at the 4 billion-cell dose with at least three months of follow-up achieved moderate or major Total Improvement Score responses.
  • Systemic sclerosis: 6 of 7 patients (86%) at the 4 billion-cell dose reached an rCRISS-25 response or greater by Day 90; 5 of 7 (71%) reached rCRISS-50.
  • Safety: infusion-related reactions occurred in five patients (12.5%), mostly grade 1, and all resolved within 24 to 48 hours.
  • Nkarta amended protocols to dose on Days 0, 2 and 4, plans to evaluate 6 billion cells per dose, and expects to report additional follow-up in the first half of 2027.

The filing

CompanyNkarta, Inc. (NKTX)
Form8-K, current report
Filed with the SECNov 9, 2026, 9:20 AM ET
Accession number0001787400-26-000027

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 9:31 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.